Who needs Humira? AbbVie projected to be the top pharma company by sales in 2028: analysts

Reports of the demise of AbbVie—concurrent with the loss of exclusivity for its mega-blockbuster drug Humira—have been greatly exaggerated.

At least that’s the consensus view of sell-side analysts polled by Evaluate Pharma, who predict that the Illinois-based pharma giant will generate more prescription sales than any company in the industry in 2028.